多发性骨髓瘤的预后和预测生物标志物的发展。
Prognostic and predictive biomarker developments in multiple myeloma.
机构信息
College of Medicine and Public Health, Level 4, Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, SA, 5042, Australia.
Flinders Medical Centre, Bedford Park, SA, 5042, Australia.
出版信息
J Hematol Oncol. 2021 Sep 23;14(1):151. doi: 10.1186/s13045-021-01162-7.
New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individual risk factors or disease characteristics. However, despite new and improved biomarkers for determining the prognosis of patients, there is currently insufficient information to utilise biomarkers to intensify, reduce or altogether change treatment, nor to target patient-specific biology in a so-called predictive manner. The ever-increasing number and complexity of drug classes to treat multiple myeloma have improved response rates and so clinically useful biomarkers will need to be relevant in the era of such novel therapies. Therefore, the field of multiple myeloma biomarker development is rapidly progressing, spurred on by new technologies and therapeutic approaches, and underpinned by a deeper understanding of tumour biology with individualised patient management the goal. In this review, we describe the main biomarker categories in multiple myeloma and relate these to diagnostic, prognostic and predictive applications.
需要基于预后和治疗决策（或预测）对多发性骨髓瘤患者进行分层的新方法，因为目前无论患者的个体危险因素或疾病特征如何，都以相似的方式进行管理。然而，尽管有用于确定患者预后的新的和改进的生物标志物，但目前尚无足够的信息来利用生物标志物来加强、减少或完全改变治疗，也无法以所谓的预测方式针对患者的特定生物学。治疗多发性骨髓瘤的药物种类不断增加且日益复杂，提高了缓解率，因此在新型疗法时代，有必要使用与临床相关的生物标志物。因此，多发性骨髓瘤生物标志物开发领域正在快速发展，新技术和治疗方法的推动，以及对肿瘤生物学的更深入理解，个体化患者管理是目标。在这篇综述中，我们描述了多发性骨髓瘤中的主要生物标志物类别，并将其与诊断、预后和预测应用联系起来。
Zotero 插件